Trial snapshot
- Formal name: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carinoma (FLC)
- Trial type: Specifically designed for fibrolamellar carcinoma
- Phase: Phase I
- Recruitment status: Active, Recruiting
- Eligible ages: 12+
- Location: Baltimore, MD (Johns Hopkins – Sidney Kimmel Comprehensive Cancer Center)
- ClinicalTrials.gov ID: NCT06027086
Overview
This phase I clinical trial is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study will test the safety and effectiveness the experimental prodrug DRP-104 in combination with an immune checkpoint inhibitor for patients with advanced stage FLC. DRP-104 is an inactive compound that is converted into a broad-acting glutamine antagonist within tumors, while mostly remaining inactivated in other healthy tissues. This study will test the hypothesis that blocking FLC’s glutamine metabolism can directly cause the death of FLC cancer cells, and also enhance a patient’s own anti-cancer immune response. (Click here to learn more about exploiting FLC’s potential metabolic weaknesses.)
Trial eligibility
(Glutamine Antagonist)While enrollment in this trial is currently open only to FLC patients 18 years old or older, enrollment should soon be open to FLC patients 12 years old and older. For more information about this study, please visit clinicaltrials.gov (NCT06027086) or contact the clinical trials team at Johns Hopkins at GIClinicalTrials@jhmi.edu.
In the video below, Dr. Marina Baretti and Dr. Mark Yarchoan of Johns Hopkins discuss the pre-clinical work that provided the scientific rationale for the effort, as well as the design and enrollment criteria for the study:
Trial contact information:
- Anna Ferguson, RN – afergus1@jhmi.edu
- Marina Baretti, MD – mbarett1@jhu.edu
Please visit clinicaltrials.gov for a comprehensive list of active trials.
The Fibrolamellar Cancer Foundation does not provide medical advice. We provide website users with information to help them better understand their health conditions and current approaches towards diagnosis, treatment and supportive care. Always seek the advice of your physician or other qualified healthcare provider.